DrugDashboards

Effer-K 20 mEq Unflavored

Potassium Bicarbonate · POTASSIUM BICARBONATE 782 mg/1 · Tablet, Effervescent · Oral · Nomax Inc.

NDC 51801-0011-30 · 30 POUCH in 1 CARTON / 1 TABLET, EFFERVESCENT in 1 POUCH · UNAPPROVED DRUG OTHER · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $0.5229 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.2$0.4$0.6Dec 2014Sep 2026$0.5229
72 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$15.69
#90 count
$47.06

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$59,354
2,071 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 2 active manufacturers+20

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for potassium bicarbonate (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program · Xywav and Xyrem

Regulatory

Application
TE code
Approval date
Patents / exclusivity

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Potassium Bicarbonate (Tablet, Effervescent)

LabelerStrengthFirst seenLast seen
Nomax Inc.POTASSIUM BICARBONATE 977.5 mg/1Jul 15, 2026Sep 3, 2026
Upsher-Smith Laboratories, Inc.POTASSIUM BICARBONATE 978 mg/1Jul 15, 2026Sep 2, 2026
Nomax Inc.POTASSIUM BICARBONATE 391 mg/1Jul 15, 2026Aug 28, 2026
Nomax Inc.POTASSIUM BICARBONATE 782 mg/1Jul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Effer-K 20 mEq Unflavored — NDC 51801-0011-30," retrieved September 3, 2026, https://drugdashboards.com/drug/51801001130.

Free to cite with attribution — see how the data is put together.